Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch^®, is excited to announce it has been selected as one of the 50 most innovative businesses in the Midlands in the 2019 Mills & Reeve “Innovation 50” campaign.

“Innovation 50” ranks 50 of the Midlands’ most innovative businesses, celebrating the region’s R&D royalty, industry ground breakers and rising stars. The report highlights innovative success stories from across the region and features 50 businesses across five categories: Business intelligence and performance; Communication; Development and inclusivity; Healthier, safer lives and Place and environment.

Medherant was selected due to its innovative transdermal drug delivery treatments for pain and CNS diseases – the TEPI Patch. TEPI Patch overcomes many of the limitations of patches currently on the market. It can be used with a wider range of drugs, a greater amount of each drug can be loaded into the patch increasing efficiency, and the patch uses a novel adhesive providing a better patient experience. 

John Burt, CEO of Medherant, commented: “We are delighted to have been selected for the Innovation 50 Campaign, recognising the talent and dedication of our team, and the value of our product. We look forward to sharing the next stage of our development as we continue to advance as a company.”

Medherant has completed two Phase I clinical studies with an Ibuprofen TEPI Patch and is discussing its further development with potential commercial partners whilst it focuses on the development of patch products to treat CNS indications.

The full report can be viewed here innovationfifty.com/see-the-report.